Magnetic-resonance-guided focused ultrasound surgery (MRgFUS) is a novel non-invasive therapeutic technique combining an MR imaging device and a focused ultrasound system, also called high-intensity focused ultrasound (HIFU). Concentration of ultrasound beams produces a highly localised (and controlled) 
below, other applications, including FDA studies for palliative treatment of bone metastases and breast cancer, are in phase II/III clinical trials.
The Sonalleve Philips system received the CE mark for treatment of uterine fibroids in 2009. Published articles in oncology refer to the ExAblate MRgFUS system only.
Current Use in the Treatment of Painful Bone Metastases
Bone is the third most common organ of metastatic dissemination after the lungs and the liver, and 50-75% of patients with bone metastases present with severe pain. Palliation of associated symptoms is the primary objective of their treatment. Current options for pain management include both local and systemic therapies. Local options include radiotherapy, surgery and percutaneous ablation by radiofrequency. Systemic treatments comprise hormone therapy, analgesics, chemotherapy and bisphosphonates. 2 MRgFUS treatment of bone metastases is based on the high acoustic absorption and low thermal conductivity of cortical bone, which allows the use of low energy levels (compared with treatment of soft tissues) to achieve temperatures >60°C at the target locations. This energy produces a coagulative necrosis without damaging the surrounding tissues, which otherwise would receive a sublethal dose. 3, 4 Two mechanisms have been postulated to explain the analgesic effect of MRgFUS: thermal denervation of the periosteum and ablation of the tumoral mass itself. In published studies, immediate pain relief is described, supporting the first hypothesis. Also, a maintained analgesic effect is found, which is explained by both mechanisms. Most treated patients present an improvement on pain scale and a reduced dose of opioids and other analgesics. Possible complications are of a thermal nature, including cutaneous burns and damage to nearby structures that are sensitive to heat, such as nerves or the intestinal wall. None of these side effects has been described in published studies, and realtime imaging control and temperature feedback through thermal mapping make such complications rare. [5] [6] [7] MRgFUS treatment of painful bone metastases has CE mark approval and is currently used in Germany, Italy, Russia and Spain. A case example is shown in Figure 2 . There is an ongoing FDA pivotal study to evaluate the effectiveness and safety of the ExAblate system in the palliative treatment of pain from metastatic bone and multiple myeloma tumours in patients who are not suitable candidates for radiotherapy. 8 This study is in the recruitment phase and is expected to include patients with osteolytic or osteoblastic lesions caused by certain clinical conditions.
Application to Breast Cancer
Breast cancer constitutes the second cause of cancer-related death in women in developed countries and is a global health issue. 9, 10 Conservative surgery followed by radiotherapy has become the gold standard in the treatment of localised breast cancer. 11 This procedure has a low mortality rate, but complications can occur, including bleeding (2-10%), infection (1-20%), seroma formation (10-80%) and chronic pain in the incision area (20-30%). 12 Technical advances in recent decades have allowed the emergence of minimally and non-invasive techniques such as cryotherapy, interstitial laser ablation, radiofrequency ablation or ultrasound ablation. [13] [14] [15] [16] MRgFUS constitutes a potentially powerful new tool for the treatment of breast cancer.
The first experience with MRgFUS in the treatment of benign tumours was published by Hynynen and colleagues in 2001. 17 In the same year, Huber and colleagues published the first case of a malignant breast tumour treated using this technique. 18 It is important to note that for a non-invasive technique to be considered equivalent to surgical extirpation, it must show necrosis of 100% of the target tumour. 19, 20 Although there is no clearly established protocol, the combination of MR and biopsy is used as the procedure of choice for detecting residual tumour. To evaluate the safety of margin ablation, Furosawa and colleagues 21 scheduled a follow-up including MR and ultrasound every three months. Gianfelice 22 also used MR 10 days and one, three and six months after the treatment as well as multiple biopsies of the affected area within six months. In cases of residual tumour, it is possible to re-treat with MRgFUS and perform a new biopsy one month later.
A number of factors must be considered when selecting candidates for the procedure, 23, 24 including a minimum distance between the tumour and the skin (to avoid skin burns) and between the tumour and the chest wall (to avoid heat accumulation in the ribs and lung). Also, the patient should be able to lie on her chest for several hours during the process.
In certain cases, this positioning may become difficult. Although there are no exact recommendations regarding the size of the target lesion, breast tumours >5cm in diameter should not be selected for treatment with MRgFUS because of the increased treatment time and reduced probability of tumour necrosis. 25 Patients with tumours ≤2cm in diameter show a 100% success rate. 26 Patients with ductal carcinoma in situ (DCIS) should also be excluded from treatment with MRgFUS because MR may under-or overestimate the extent of DCIS, which may MRgFUS has also been used to treat acute brain infarction, 34 although this application will not be described in this article.
Initial Application in Prostate Cancer
Prostate carcinoma is a public health problem worldwide, with an increasing incidence due to ageing of the population. It is estimated that in 2015, 450,000 new cases will be diagnosed in the US alone. Current treatments for prostate cancer include surgery, radiotherapy and brachytherapy. The most important complications related to radical prostatectomy include deep vein thrombosis, pulmonary embolism, urinary incontinence and impotence. Radiation therapy has similar complications plus gastrointestinal toxicity. The search for image-guided minimally/non-invasive methods with a low mortality rates is of great interest. 35 New therapies include cryotherapy, 36 photodynamic therapy 37 and HIFU. The first results of application of HIFU to localised prostate carcinoma were published by Gelet et al. 38 Pre-clinical MRgFUS trials have been carried out in canine models. The key differences between MR-guided and ultrasound-guided systems is the ability of MR to yield realtime temperature mapping and procedure feedback during the ablation. The possibility of performing treatment in a single session with a low complication rate and without the need to irradiate the patient explain the very high interest in using MRgFUS to treat prostate cancer.
Treatment of Hepatocellular Carcinoma
As in other malignancies, the gold standard for the treatment of hepatocellular carcinoma is surgical resection. However, about 85% of patients are not suitable candidates for surgery, and the five-year survival rate is very low. This situation has fostered the development of novel minimally invasive techniques such as microwave and laser ablation, cryotherapy and radiofrequency ablation. The interest in using
MRgFUS instead of these techniques is due to its true non-invasive character: since there is no need to insert any type of guide or needle into the hepatic parenchyma, the risk of surgical complications is eliminated. Starting with focused ultrasound, studies have been published on animal models and individual cases. [39] [40] [41] There are still some limitations to be overcome, including the ability to treat lesions behind the ribs and synchronise sonications with respiratory motion.
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Application to Targeted Drug Delivery
The application of MRgFUS to targeted drug delivery is a potentially great innovation and advance in the field of medical oncology since it may help to prevent systemic toxicities and achieve increased 
